Merck & Company Inc (MRK)vs10X Genomics Inc (TXG)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
TXG
10X Genomics Inc
$31.04
-7.34%
HEALTHCARE · Cap: $3.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10196% more annual revenue ($65.77B vs $638.78M). MRK leads profitability with a 13.6% profit margin vs -3.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
TXG
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+68.7%
Fair Value
$61.17
Current Price
$31.04
$30.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : TXG
The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while TXG is a turnaround play — different risk/reward profiles.
TXG carries more volatility with a beta of 2.11 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 25/100). TXG offers better value entry with a 68.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?